Christopher Kim
CIK: 0002040022
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Apimeds Pharmaceuticals US, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Oct 15, 2025APUS
Apimeds Pharmaceuticals US, Inc.
Award(A)DirectStock Option (right to buy)
3K shares- - May 16, 2025APUS
Apimeds Pharmaceuticals US, Inc.
Award(A)Direct250K shares- - May 14, 2025APUS
Apimeds Pharmaceuticals US, Inc.
Purchase(P)Direct7.7K shares at avg. $1.86$14K - May 13, 2025APUS
Apimeds Pharmaceuticals US, Inc.
Purchase(P)Direct19.8K shares at avg. $1.82$36K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 15, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | Award(A) Stock Option (right to buy) | 3,000 | - | - | Direct |
| May 16, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | Award(A) | 250,000 | - | - | Direct |
| May 14, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | Purchase(P) | 7,730 | $1.86 | $14,378 | Direct |
| May 13, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | Purchase(P) | 19,770 | $1.82 | $35,981 | Direct |
1-4 of 4 transactions
About Kim Christopher
Kim Christopher (SEC CIK 0002040022) files insider reports with the SEC as Chairman and CMO of Apimeds Pharmaceuticals US, Inc. (APUS).
Signal8 holds 4 ownership filings by Kim Christopher (1 Form 3, 3 Form 4), filed between May 8, 2025 and Oct 17, 2025. Those filings report 4 transactions, from May 13, 2025 to Oct 15, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Kim Christopher's filings is in HOPEWELL, NJ.
Recent filings by Kim Christopher
Other insiders filing for Apimeds Pharmaceuticals US, Inc. (APUS)
- Sherb Eric Michael, Chief Financial Officer
- Menon Vin, Co-Chief Executive Officer
- Inscobee Inc., 10% Owner
- Weintraub Bennett, Director
- Yoon Hankil, Director
- Koo Jakap, Director